NEW YORK, Nov. 17 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc. announced today that its wholly-owned subsidiary Biomedical Diagnostics, LLC (Biomedical) in Ann Arbor, MI, has obtained continuance of its high-complexity CLIA certificate of compliance from the Michigan Department of Community Health (MDCH).
CLIA certification indicates that Biomedical is operating its clinical laboratory services for its Mammastatin Serum Assay (MSA) at procedural and quality levels consistent with the highest industry standards. The continuation was based on a recently completed independent standard bi-annual audit by the Michigan Department of Community Health.
Certification under CLIA, or Clinical Laboratory Improvement Amendments of 1988, is required of all reference laboratories that offer clinical testing services. The CLIA program is administered by each state under the auspices of the United States Department of Health & Human Services Health Care Financing Administration.
The MSA is a blood test that assesses women's breast health. In scientific correlation studies women who have a high test result have been shown to have a lower risk of breast cancer than women who have a low test result. The potential of the MSA is to provide a simple blood test that could be capable of much earlier awareness of the risk of breast cancer so that appropriate monitoring or preventive therapy can be implemented. The MSA test is currently available to physicians through ARUP Laboratories in Salt Lake City, Utah, or directly through Biomedical's laboratory services.
"Our clinical laboratory services process for the MSA has been CLIA certified since 2001," said Jim Arthurs, president of Biomedical Diagnostics. "While the latest standard audit and subsequent certificate are significant, what is more important is that it says to our customers that the consistency and accuracy of our test services have not wavered."
More information about Biomedical Diagnostics, the MSA test, and how to order a test can be obtained at www.bio-diagnostics.com.
About Genesis Bioventures, Inc.
Genesis Bioventures, Inc. is a biomedical development corporation focusing on the development and marketing of novel diagnostics and therapeutics in oncology and neurodegenerative diseases.
Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com, www.gnsbio.com Aurelius Consulting Group: (800) 644-6297, info@runonideas.com, www.runonideas.com
Genesis Bioventures, Inc.CONTACT: GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com,www.gnsbio.com; Aurelius Consulting Group: (800) 644-6297,info@runonideas.com, www.runonideas.com
